BTIG Rates Haemonetics (HAE) buy, $84 Price Target
BTIG maintains its buy rating for Haemonetics with an $84 price target, a 15.81% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated Haemonetics Corporation ($HAE) "buy" with a $84 price target on June 17, 2026.
Since the rating, $HAE is up 0.2% after 1 week, up 7.0% after 1 month and up 62.6% to date (from the $72.73 close on Jun 17, 2026).
HAE
Haemonetics Corporation
Key Points
- BTIG reiterated its buy rating on Haemonetics Corporation, setting a price target of $84.
- BTIG's $84 price target implies 15.81% upside from Haemonetics Corporation's ($HAE) current $72.53 share price.
- Haemonetics shares traded near $74.43, with a market cap of about $3.38 billion and a forward P/E of 12.92.
- Insiders at Haemonetics have recently engaged in both buying and selling, with notable trades by top executives.
Get $HAE trade alerts by text
We text you when insiders, Congress or big funds trade $HAE. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Haemonetics Corporation alert may contain errors. Disclosures
On June 17, 2026, BTIG reiterated its buy rating for Haemonetics Corporation (NYSE:HAE), maintaining a price target of $84. The stock was trading at around $74.43 at the time of the report.
Haemonetics Corporation Stock Down 40.2%
Shares of NYSE:HAE traded near $74.43. Haemonetics has a market cap of approximately $3.38 billion, with a P/E ratio of 36.31 and a forward P/E of 12.92. The stock has a beta of 0.54, indicating lower volatility compared to the market. Over the past 52 weeks, the stock has ranged from $47.32 to $87.32. Its 50-day moving average is $62.82, while the 200-day moving average is $63.61. The company maintains a current ratio of 2.95 and a quick ratio of 1.64, with a debt-to-equity ratio of 160.08.
$HAE price target
Haemonetics Corporation daily closes and this analyst's $84 target. Not advice.
Recent Earnings
Haemonetics reported revenue of about $1.33 billion, showing a growth of 4.8%. The company's net margin stands at 7.29%, with a return on equity of 12.03%. Earnings per share (EPS) were $2.05. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Haemonetics Corporation
Recent insider activity at Haemonetics includes both buying and selling. On May 15, 2026, James Darecca, EVP and CFO, bought 29,312 shares. On the same day, President and CEO Christopher Simon sold 9,681 shares at $56.29 each. Other notable sales include those by VP and Chief Accounting Officer Maryanne Maunsell and SVP of Human Resources Laurie Miller on June 5, 2026, each selling shares at $71.28.
Analysts Set New Price Targets
On June 17, 2026, BTIG reiterated its buy rating with a price target of $84. Mizuho maintained its buy rating on June 15, 2026, with an $85 target. B of A Securities upgraded the stock to a buy with an $80 target on May 22, 2026. The consensus among analysts is a buy rating, with an average target price of $83.10 based on 10 analyst opinions.
About Haemonetics Corporation
Haemonetics Corporation, headquartered in Boston, Massachusetts, is a medical technology company specializing in hospital technologies and solutions. Their products include automated plasma collection systems and donor management software. The company also provides surgical and critical care solutions, such as the TEG 6s system and Cell Saver Elite +, among others. Led by CEO Christopher A. Simon, Haemonetics employs around 3,009 people.
Bottom Line
BTIG's reiteration of a buy rating on Haemonetics reflects positive sentiment and a target price that suggests potential upside. The company's financial metrics, including a solid forward P/E ratio and steady revenue growth, provide a stable outlook. Investors often track such ratings for insights, though it's important to remember that these are based on historical and current data, not future predictions.
Related Filing Alerts
Source: BTIG's rating change on $HAE (Jun 17, 2026). Written by software, not financial advice. How we make alerts